Hutch News

Hutch News

Stories tagged 'Stanley R Riddell'

Dr. Marie Bleakley named Gerdin Family Endowed Chair for Leukemia Research

Pediatric cancer physician-scientist feted at rooftop reception

Aug. 30, 2018 | By Susan Keown / Fred Hutch News Service

Fred Hutch pediatric leukemia specialist Dr. Marie Bleakley has been named the Gerdin Family Endowed Chair for Leukemia Research, which was funded by the generosity of a patient family from Iowa.

View story >


Want to make better T-cell therapies? First, figure out how they work.

New study maps out activities, effects of widely used components in cellular immunotherapies

Aug. 21, 2018 | By Susan Keown / Fred Hutch News Service

This work "gives us a direction" to create better, next-gen versions of this type of cancer immunotherapy, called CAR T-cell therapy, the researchers said.

View story >


His immune system eradicated his melanoma. Could other patients’ bodies be taught to do the same thing?

How one man’s T cells are guiding the development of next-gen immunotherapies

June 19, 2018 | by Susan Keown / Fred Hutch News Service

Chris Pope's immune system eradicated his stage 4 melanoma on an immunotherapy clinical trial. Is it possible to genetically reprogram other patients' to do the same thing?

View story >


Tinkering with T cells

How researchers are tweaking engineered immune cells’ cancer-targeting receptors — and why it matters

May 15, 2018 | By Susan Keown / Fred Hutch News Service

These immune cells are the cornerstone of emerging cancer therapies. And their unimaginably tiny, cancer-targeting molecular weapons — their receptors — are the focus of intense scientific tinkering.

View story >


Science without borders

At Fred Hutch and other U.S. research centers, a global village works to cure cancer and other diseases

Oct. 16, 2017 | By Mary Engel / Fred Hutch Research Center

Fred Hutch, like other major U.S. cancer research centers, attracts top scientists from around the world working to cure cancer, HIV and other diseases

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.